Table 4 Adverse Events that are likely related to antiretroviral therapy at visit +1

Total number of AEs found NE group: n = 150; E group: n = 75

2 (1.3%)

14 (18.7%)

OR 16.8; 95% CI: 3.7-76.9; p  < 0.001

Number of AEs excluding patients with viral load > 50 copies/mL at visit −1 NE group: n = 141; E group: n = 62

2 (1.4%)

11 (17.7%)

OR 14.9; 95% CI: 3.2-70.0; p  < 0.001

Number of AEs excluding patients with viral load > 50 copies/mL at baseline visit NE group: n = 136; E group: n = 64

2 (1.5%)

13 (20.3%)

OR 17.0; 95% CI: 3.7-78.3; p  < 0.001

Number of AEs excluding patients who recently started treatment with FDCs NE group: n = 132; E group: n = 63

1 (0.8%)

11 (17.5%)

OR 27.1; 95% CI: 3.4-215.8; p  < 0.001

Number of AEs excluding patients who recently started treatment with efavirenz NE group: n = 84; E group: n = 50

2 (2.4%)

12 (24.0%)

OR 13.5; 95% CI: 2.9-63.5; p  < 0.001